Lv7
5000 积分 2023-04-18 加入
Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)
8天前
已关闭
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study
8天前
已完结
New Binding Sites for JAK2 Inhibition in Myeloproliferative Neoplasms: Structural Insights, Therapeutic Potential, and Future Directions
11天前
已完结
Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms
11天前
已完结
Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia
14天前
已完结
Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes
24天前
已完结
A pharmacological profile of pacritinib for the treatment of myelofibrosis
24天前
已完结
Novel Strategies Targeting Mutant Calreticulin in Essential Thrombocythemia and Myelofibrosis
24天前
已关闭
Modulators of the hepcidin pathway in polycythemia vera and myelofibrosis
24天前
已完结
Combination treatments for myelofibrosis in jak inhibitor-naive patients: evidence, rationale, and clinical direction
24天前
已完结
皖公网安备34019202002308
